Here is how DexCom (DXCM) and Adaptive Biotechnologies (ADPT) have performed compared to their secto

Truist Securities analyst Richard Newitter maintains DexCom (NASDAQ:DXCM) with a Buy and raises t

Mizuho analyst Anthony Petrone maintains DexCom (NASDAQ:DXCM) with a Outperform and raises the pr

DexCom's G7 15 Day wins Health Canada authorization, offering longer wear, high accuracy and smart f

Dexcom G7 15 Day is the longest‑lasting and most accurate1-4 CGM system authorized by Health Canada,

BURNABY, British Columbia--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ: DXCM), the global leader in glucos

[url="]DexCom, Inc.[/url] (NASDAQ: DXCM) today announced that it plans to release its second quarter

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investi

DexCom, Inc.  DXCM is well positioned for growth in the coming quarters, supported by the significan

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or ob

DexCom faces a pivotal transition as GLP-1 adoption threatens its core insulin-treated diabetes mark

DXCM outpaces Abbott with expanding CGM access, new product launches and broader coverage, making it

DXCM's redesigned Stelo app is set for a July U.S. rollout, with international expansion and pediatr

Wall Street analysts changed outlook on top names, including MCRB, SAFX. See analyst ratings page fo

Deutsche Bank analyst Kieran Ryan initiates coverage on DexCom (NASDAQ:DXCM) with a Buy rating an

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, to

The GLP-1 revolution is quietly continuing even as investor interest has moved on to more timely top

TD Cowen analysts estimate that the total addressable market for longevity healthcare exceeds $250 b

Until recently, it had been a lackluster year for the healthcare sector. From high medical utilizati

In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Bioscienc

DexCom's FDA-cleared Stelo OTC glucose biosensor now covers children aged above 2 years not using in

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the

FDA Clears Dexcom's OTC Stelo CGM For Children Ages 2 And Older, Expanding Access To Real-Time G

Piper Sandler analyst Matt O'Brien maintains DexCom (NASDAQ:DXCM) with a Overweight and raise

The U.S. Food and Drug Administration said on Friday it has expanded the ​use of Dexcom's Stelo Gluc

https://www.fda.gov/news-events/press-announcements/fda-clears-first-over-counter-continuous-glucose

Drug wholesaler Pharmsource LLC said it was unaware the Dexcom glucose sensors ​it bought from licen

TD Cowen analyst Joshua Jennings maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price t

Mizuho analyst Anthony Petrone maintains DexCom (NASDAQ:DXCM) with a Outperform and raises the pr

DexCom CONNECT trial found G7 reduced A1C and improved glucose control in Type 2 diabetes patients n

Dexcom sponsored CONNECT randomized controlled trial expected to help establish new standard of care

Stifel analyst Jonathan Block maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price targ

CONNECT study will demonstrate Dexcom CGM benefits for adults with Type 2 diabetes not using insulin

Citigroup analyst Joanne Wuensch maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price t

Through ongoing quality and accounting reviews, Dexcom discovered two lots of scrapped product were

Canaccord Genuity analyst William Plovanic maintains DexCom (NASDAQ:DXCM) with a Buy and lowers t

B of A Securities analyst Travis Steed maintains DexCom (NASDAQ:DXCM) with a Buy and lowers the p

Barclays analyst Matt Miksic maintains DexCom (NASDAQ:DXCM) with a Underweight and lowers the pri

DexCom, Inc. (Nasdaq: DXCM), a global leader in continuous glucose monitoring, today announced Dexco

DexCom Sets 2030 Margin Targets, Projects Double-Digit Revenue Growth, Authorizes $1 Billion Share B

Will Add Two Independent Directors with MedTech and Operations Experience to be Named at a Later Dat

Citigroup analyst Joanne Wuensch maintains DexCom (NASDAQ:DXCM) with a Buy and lowers the price t

Canaccord Genuity analyst William Plovanic maintains DexCom (NASDAQ:DXCM) with a Buy and raises t

TD Cowen analyst Joshua Jennings maintains DexCom (NASDAQ:DXCM) with a Buy and lowers the price t

Barclays analyst Matt Miksic maintains DexCom (NASDAQ:DXCM) with a Underweight and lowers the pri

2026 Annual GuidanceDexcom is raising fiscal year 2026 guidance for Non-GAAP Operating Margin and Ad